Literature DB >> 3109062

Tissue plasminogen activators in breast cancer.

G T Layer, K G Burnand, P J Gaffney, S A Cederholm-Williams, M Mahmoud, S Houlbrook, M Pattison.   

Abstract

Increased levels of tissue fibrinolytic activity have been detected in some malignant tumours and they have been implicated in metastatic spread. We have investigated tissue plasminogen activator (tPA) and urokinase (UK) in 26 breast carcinomas and 13 benign breast biopsies. Tissue extracts were analysed for overall fibrinolytic activity on fibrin plates and by fibrin-overlay zymography after electrophoresis on SDS-PAG. Supernatants of the extracts were analysed by an antigenic immunoassay (ELISA) and a functional bioimmunoassay (BIA) using polyclonal antibodies. Total ELISA and BIA results correlated (P less than 0.001) and all the tissues contained similar tPA levels. Malignant extracts contained significantly increased UK compared with benign extracts (1.60 +/- 0.37 iu, 0.36 +/- 0.16 iu; P less than 0.002). Zymography showed no high molecular weight inhibitor complexes and UK was almost exclusively confined to the malignant tissues (P much less than 0.02). The results suggest that malignant transformation of breast tissue is associated with the significantly increased production of UK. This may be responsible for the characteristics of malignancy or it may be a growth factor.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3109062     DOI: 10.1016/0049-3848(87)90323-9

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  Plasma levels of D-dimer: a crosslinked fibrin-degradation product in female breast cancer.

Authors:  C G Mitter; C C Zielinski
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Hormonal regulation of plasminogen activator and peroxidase activities in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors and the rat uterus.

Authors:  K Inada; J Yamashita; T Yoshimura; S Matsuo; Y Nakashima; S Yamashita; A Misumi; M Ogawa
Journal:  Jpn J Surg       Date:  1991-03

Review 3.  The plasminogen-plasmin system in malignancy.

Authors:  H C Kwaan
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

4.  Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer.

Authors:  J H de Witte; C G Sweep; J G Klijn; N Grebenschikov; H A Peters; M P Look; T H van Tienoven; J J Heuvel; J Bolt-De Vries; T J Benraad; J A Foekens
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

5.  Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer.

Authors:  J Yamashita; M Ogawa; S Yamashita; Y Nakashima; T Saishoji; K Nomura; K Inada; I Kawano
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

Review 6.  Haemostasis in malignant disease.

Authors:  M J Auger; M J Mackie
Journal:  J R Coll Physicians Lond       Date:  1988-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.